Recovery of serum testosterone following neoadjuvant and adjuvant androgen deprivation therapy in men treated with prostate brachytherapy

Table 2 Univariate and multivariate analyses of factors associated with testosterone recovery to supracastrate levels in the long-term usage group

Factor	Univariate analysis			Multivariate analysis
	HR	95%CI	P value	HR	95%CI	P value
At brachytherapy
Body mass index
< 25	1.249	0.733-2.130	0.413	-	-	-
≥ 25	1.000	(reference)		-	-	-
Diabetes
No	1.262	0.505-3.156	0.687	-	-	-
Yes	1.000	(reference)		-	-	-
Hypertension
No	0.959	0.572-1.608	0.873	-	-	-
Yes	1.000	(reference)		-	-	-
At cessation
Age
< 73 yr	1.98	1.182-3.317	0.009	2.020	1.190-3.429	0.009
≥ 73 yr	1.000	(reference)		1.000	(reference)
T level at baseline1
< 10 ng/dL	1.000	(reference)		1.000	(reference)
≥ 10 ng/dL	2.261	1.316-3.883	0.003	2.327	1.354-4.000	0.002
Drug formulation
Duration of activity
1 mo	1.000	(reference)		-	-	-
3 mo	1.419	0.821-2.454	0.209	-	-	-
Material
Goserelin	0.973	0.579-1.635	0.917	-	-	-
Leuprorelin	1.000	(reference)		-	-	-

¹Testosterone level at baseline was measured 1 mo before the cessation of androgen deprivation therapy. Statistical significance was assessed at P < 0.05. T: Testosterone.